Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Arthritis Rheum. 2010 Nov;62(11):3322–3333. doi: 10.1002/art.27659

Figure 2.

Figure 2

A. W/Wv mice were engrafted with B6 or C5aR−/− BMMC × 10 weeks followed by initiation of K/BxN arthritis (n=5 mice per group, representative of 5 independent experiments). B. Quantitation of engrafted mast cells in ankles from A, n=23–26 mice/group, B6 vs. C5aR−/− p=ns. C. Paw edema (flare) 30 minutes after i.p. injection of 150µL K/BxN serum into a B6 mouse. D. Timecourse of flare, n=5 mice representative of 4 experiments. E. Flare 30m after injection of K/BxN serum in B6, C5aR−/−, mast cell-deficient (W/Wv) and FcRγ−/− mice lacking FcγRIII (mice, n=4–12 mice/group from 3 experiments. Of these, 5 B6 and 4 C5aR−/− mice received a second serum injection on day 2 with day 7 clinical scores of 11.6+/−0.4 and 0+/−0 respectively (p<0.0001). F. Degranulation of synovial mast cells assessed histologically 24h after administration of K/BxN serum.